TY - JOUR
T1 - A comprehensive overview of living with Sjögren’s
T2 - results of a National Sjögren’s Foundation survey
AU - McCoy, Sara S.
AU - Woodham, Miguel
AU - Bunya, Vatinee Y.
AU - Saldanha, Ian
AU - Akpek, Esen K.
AU - Makara, Matthew A.
AU - Baer, Alan N.
N1 - Funding Information:
Dr. McCoy was supported by the Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS), grant 1KL2TR002374. Dr. Baer is supported by NIH/NIDCR contract 75N92019P00427. Dr. Bunya is supported by NIH/NEI R01 EY026972. Mr. Makara’s time was paid for by the Sjögren’s Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).
PY - 2022/7
Y1 - 2022/7
N2 - To gain insight into the Sjögren’s disease (SjD) patient experience using a survey generated by patients and providers. We evaluated the results of the 2016 Sjögren’s Foundation survey, with 25 questions designed in a collaborative effort between the Foundation, patients with SjD, SjD provider experts, and a marketing research company. We used descriptive statistics to provide a thorough understanding of SjD demographics, symptoms, quality of life (QoL), cost, and treatments. Analyses revealed high symptoms, QoL, and financial burdens in SjD. Dry mouth and eye were the most commonly reported symptoms (94 and 93%, respectively). The most frequent extra-glandular symptoms included fatigue, dry or itchy skin, and morning stiffness. The top three aspects of QoL most impaired included (i) sex life (53%), (ii) participating in hobbies/social activities/extracurricular activities (52%), and (iii) job/career or ability to work (49%). SjD respondents commonly reported taking health food supplements/remedies, vitamin D, and exercising, in addition to taking treatments for symptomatic dryness. SjD costs were high, including a total yearly cost, on average, of $2026 for dental care. SjD respondents reported that dryness and risk factors for lymphoma and fatigue are essential to address with new therapies. In this comprehensive overview of the SjD experience, we demonstrated a high burden of disease to SjD respondents, including symptoms, QoL, and financial burden. We also identify the top goals of therapy for new systemic SjD therapies.
AB - To gain insight into the Sjögren’s disease (SjD) patient experience using a survey generated by patients and providers. We evaluated the results of the 2016 Sjögren’s Foundation survey, with 25 questions designed in a collaborative effort between the Foundation, patients with SjD, SjD provider experts, and a marketing research company. We used descriptive statistics to provide a thorough understanding of SjD demographics, symptoms, quality of life (QoL), cost, and treatments. Analyses revealed high symptoms, QoL, and financial burdens in SjD. Dry mouth and eye were the most commonly reported symptoms (94 and 93%, respectively). The most frequent extra-glandular symptoms included fatigue, dry or itchy skin, and morning stiffness. The top three aspects of QoL most impaired included (i) sex life (53%), (ii) participating in hobbies/social activities/extracurricular activities (52%), and (iii) job/career or ability to work (49%). SjD respondents commonly reported taking health food supplements/remedies, vitamin D, and exercising, in addition to taking treatments for symptomatic dryness. SjD costs were high, including a total yearly cost, on average, of $2026 for dental care. SjD respondents reported that dryness and risk factors for lymphoma and fatigue are essential to address with new therapies. In this comprehensive overview of the SjD experience, we demonstrated a high burden of disease to SjD respondents, including symptoms, QoL, and financial burden. We also identify the top goals of therapy for new systemic SjD therapies.
KW - Cost
KW - Quality of life
KW - Sjӧgren’s disease
KW - Symptoms
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85125760084&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125760084&partnerID=8YFLogxK
U2 - 10.1007/s10067-022-06119-w
DO - 10.1007/s10067-022-06119-w
M3 - Article
C2 - 35257256
AN - SCOPUS:85125760084
SN - 0770-3198
VL - 41
SP - 2071
EP - 2078
JO - Clinical Rheumatology
JF - Clinical Rheumatology
IS - 7
ER -